Tryptophan metabolism has long been recognised as a biochemical intersection where diet, metabolism, and brain function converge. Central to serotonin biosynthesis is tryptophan hydroxylase (TPH), the rate-limiting enzyme that converts dietary tryptophan into serotonin (5-HT). For decades, TPH1 was viewed as the “peripheral” isoform and TPH2 as the “brain” isoform. However, two recent studies are reframing this view, showing that TPH2 is not confined to the brain but also functions in peripheral systems, including adipose tissue, where it emerges as a driver of obesity-linked metabolic dysfunction and as a molecular player in the neurobiology of autism.
In the central nervous system, TPH2 is critical for producing brain serotonin, a neurotransmitter and neurotrophic factor essential for regulating mood, social behaviour, communication, and cognitive flexibility. A new study by Golebiowska et al., using a rat model, shows that congenital loss of TPH2 (and thus central serotonin) leads to sex-specific alterations in autism-related behaviours. TPH2-deficient males displayed heightened aggression, copulatory-like behaviours, and cognitive inflexibility, while females showed reduced social approach and compulsive marble-burying. These findings highlight TPH2 as a key regulator of socio-communicative and repetitive behaviours, which are core features of autism spectrum disorder (ASD), and underline how serotonergic dysregulation early in life can alter neurodevelopmental trajectories.
A second metabolic study published this month by Park et al. shows that TPH2’s influence extends far beyond the brain. In diet-induced obesity and genetically obese (ob/ob) mice, adipocyte TPH2 expression was dramatically upregulated, mirroring findings in subcutaneous fat from obese humans. Overexpression of TPH2 in white adipose tissue increased circulating 5-HT, suppressed brown adipose tissue thermogenesis, promoted hepatic steatosis, impaired insulin signalling, and worsened glucose tolerance. Conversely, deleting TPH2 from adipocytes improved glucose homeostasis, increased brown adipose tissue thermogenesis, reduced adipose inflammation, and protected against metabolic complications of obesity, although total body weight gain remained unaffected.
Importantly, the Park et al. study identifies insulin as the upstream driver. Obesity-associated hyperinsulinemia activated mTORC1–SREBP1 signalling, which increased TPH2 transcription in adipocytes. In humans, subcutaneous adipose TPH2 mRNA levels correlated positively with fasting plasma insulin concentrations, whereas TPH1 did not. This positions TPH2 as both a target and a mediator that reinforces insulin resistance: insulin drives adipose TPH2 upregulation, which elevates peripheral serotonin, which in turn dampens thermogenesis, alters lipid metabolism, and further entrenches metabolic dysfunction.
The overlap becomes particularly intriguing when considering that insulin is also implicated in neurodevelopmental and psychiatric disorders. Insulin signalling influences synaptic plasticity, neurotransmitter homeostasis, and serotonergic tone in the brain. In obesity, chronically elevated insulin may act on both central and peripheral compartments by upregulating adipose TPH2 to disrupt metabolic regulation, while indirectly altering brain serotonin pathways that are already sensitive to TPH2 status. In individuals with neurodevelopmental vulnerabilities, such as ASD-related serotonergic dysregulation, the added metabolic stress of obesity and hyperinsulinemia may exacerbate behavioural and cognitive symptoms.
Taken together, these studies provide a new perspective on TPH2 as a bidirectional link between body and brain:
-
- In the brain, TPH2 governs serotonin-dependent social and cognitive behaviours, influencing autism-relevant traits.
-
- In adipose tissue, insulin-induced TPH2 activity controls peripheral serotonin production, shaping thermogenesis, hepatic lipid handling, and glucose metabolism.
This dual role means that TPH2 is not merely a metabolic enzyme or a neurodevelopmental factor, but a molecular bridge connecting two of the fastest-growing public health challenges: obesity and autism. Targeting TPH2 pharmacologically or modulating its insulin-driven expression could represent a novel therapeutic strategy to improve both metabolic health and neuropsychiatric outcomes, especially in individuals at the intersection of these conditions.